Justin Arnall, PharmD, BCOP, Breanna Taylor, PharmD, BCOP, and Jeff Goff, RPh, MS, discuss how expanding IV iron indications across cardiology, oncology, and CKD are reshaping the pharmacist's role in formulary strategy, product stewardship, and patient identification.
Revumenib and ziftomenib in NPM1-mutated AML: practical guidance on differentiation syndrome, QTc monitoring, and drug interactions.
Explore the latest advancements in treating transplant-ineligible multiple myeloma, highlighting new therapies and clinical trial outcomes for improved patient care.
Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.
